Etentamig
Multispecific antibody
Also known as ABBV-383
Evidence outlook · regulatory review
Multiple Myeloma: application submitted to FDA
AbbVie submits a BLA for etentamig in relapsed or refractory multiple myeloma (2026-10-27). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
CERVINO (NCT06158841): This was a randomized, open-label Phase 3 trial with 421 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-03. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.
Also in development:AL Amyloidosis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03933735 NCT03933735 · Multiple Myeloma Registry: NCT03933735 | 1/2 | Number of Participants with Dose-limiting toxicities (DLT) (Day 21); Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs) (Up to 3 Years); Maximum Observed Plasma Concentration of TNB-383B (Cmax) (Week 12); Time to Cmax of TNB-383B (Tmax) (Week 12); Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUClast) (Week 12); Clearance (CL) of TNB-383B (Week 12); Terminal Phase Elimination Rate Constant (Beta) of TNB-383B (Week 12); Terminal Half-Life (t1/2) of TNB-383B (Week 12); Number of Participants with of Anti-drug Antibody (ADA) (Up to Month 48) 2026-05 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 4 more trials
CERVINO NCT06158841 · Multiple Myeloma This was a randomized, open-label Phase 3 trial with 421 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-03. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate. Registry: NCT06158841 | 3 | Progression Free Survival (PFS) (Up to Approximately 5 Years); Objective Response Rate (ORR) (Up to Approximately 5 Years) 2027-12 | Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03). | Partial signal | link ↗ |
NCT05286229 NCT05286229 · Relapsed/Refractory Multiple Myeloma Registry: NCT05286229 | 1 | Number of Dose-Limiting Toxicities (DLT) (Up to Approximately 12 Months); Number of Participants with Adverse Events (AE) (Up to Approximately 24 Months) 2026-03 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT07095452 NCT07095452 · Multiple Myeloma Registry: NCT07095452 | 2/3 | Phase 2 and 3: Percentage of Participants with Adverse Events (AE)s (Up to Approximately 16 Years); Phase 2: Change in Clinical Activity (Up to Approximately 52 weeks); Phase 3: Minimal Residual Disease (MRD) Negative CR Rate (Up to Approximately 52 weeks); Phase 3: Progression-Free Survival (PFS) (Up to Approximately 130 Months) 2041-03 | In progress: results expected 1 Mar 2041 | not yet graded | link ↗ |
NCT07728188 NCT07728188 · Relapsed or Refractory Multiple Myeloma Registry: NCT07728188 | 3 | Safety Run-In: Number of Participants With Adverse Events (AE)s (Up to Approximately 75 Months); Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment (Up to Approximately 75 Months); Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment (Up to Approximately 75 Months) 2033-02 | In progress: results expected 1 Feb 2033 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 1/2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other BCMA x CD3 drugs
Elranatamab, Linvoseltamab, Teclistamab, F182112, Gamgertamig (CM336) and 6 more. Compare all 12 BCMA x CD3 drugs
This mechanism is crowded: 11 other tracked programmes target it, 3 of them ahead of this one.
This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Etentamig: this drug | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Anselamimab (Amlypave) | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Daratumumab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Cizutamig | Phase 1(overall) | Multispecific antibody | BCMA x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Birtamimab | Discontinued | Monoclonal antibody | Misfolded immunoglobulin light chain (AL amyloid) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Etentamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (1)
February 2028 (1)
What to watch
2029 (1)
August 2029 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
2033 (2)
2034 (1)
December 2034 (1)
What to watch
2035 (1)
December 2035 (1)
What to watch
2036 (3)
March 2036 (1)
What to watch
September 2036 (2)
2041 (1)
March 2041 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent